| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT07523009 CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA |
overall status: "Not Yet Recruiting" → "Withdrawn" |
| 2026-06-05 | NCT07523009 CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA |
critical why stopped: null → "The registration of this research plan was incorrect. A new registration has been re-applied for." |
| 2026-06-05 | NCT07523009 CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA |
Enrollment reduced: 43 -> 0 participants |
| 2026-06-05 | NCT07532408 Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA |
overall status: "Not Yet Recruiting" → "Withdrawn" |
| 2026-06-05 | NCT07532408 Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA |
critical why stopped: null → "The registration of this research plan was incorrect. A new registration has been done." |
| 2026-06-05 | NCT07532408 Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA |
Enrollment reduced: 43 -> 0 participants |
| 2026-06-05 | NCT07522996 Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA |
overall status: "Not Yet Recruiting" → "Withdrawn" |
| 2026-06-05 | NCT07522996 Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA |
critical why stopped: null → "The registration of this research plan was incorrect. A new registration has been re-applied for." |
| 2026-06-05 | NCT07522996 Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA |
Enrollment reduced: 90 -> 0 participants |
| 2026-05-23 | NCT07197450 Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism |
date change Primary completion pushed: 2026-04-15 -> 2026-07-15 |
| 2026-05-23 | NCT07197450 Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism |
date change Completion pushed: 2026-04-30 -> 2026-07-30 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07639177 Faecal Microbiota Transplantation in Patients With Refractory Rheumatoid Arthritis | Phase 2 | Not Yet Recruiting |
| 2026-06-10 | NCT07640048 Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study | Recruiting | |
| 2026-06-09 | NCT07635134 Study on the Diagnostic Cut-off Point of 24-hour Urinary Aldosterone Measured by Liquid… | Recruiting | |
| 2026-06-08 | NCT07634497 HAL-PDT for Cervical Intraepithelial Neoplasia Grade 2 | Not Yet Recruiting | |
| 2026-06-04 | NCT07625436 Artificial Intelligence for Rare Disease Diagnosis | Not Yet Recruiting | |
| 2026-06-04 | NCT07625904 Effects of a Five-Dimensional Intervention Program Based on Inner Strength on… | Completed | |
| 2026-06-03 | NCT07624682 cRCT of AI Agent in Clinital Resoning Training | Enrolling by Invitation | |
| 2026-06-02 | NCT07621120 Wearable Accelerometers for Predicting Perioperative Risk in Elderly Patients | Recruiting | |
| 2026-06-01 | NCT07617155 GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis | Phase 4 | Not Yet Recruiting |
| 2026-06-01 | NCT07618416 Machine Learning Model Based on Baroreflex Sensitivity for Predicting Post-Induction… | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07580950 | The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic… | Functional Hypothalamic Amenorrhea | Recruiting |
| NCT07334535 | Isa-VRD in TIE HRMM | Multiple Myeloma | Not Yet Recruiting |
| NCT07336680 | Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in… | Esophagogastroduodenoscopy | Not Yet Recruiting |
| NCT07396701 | Chinese Adaptive Randomised Pneumonia Trial With Respiratory Failure | Severe Pneumonia With Respiratory Failure | Not Yet Recruiting |
| NCT07466251 | PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke | Acute Ischemic Stroke AIS | Not Yet Recruiting |
| NCT07264738 | Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy… | Esophagogastroduodensocopy (EGD) Procedure | Active, Not Recruiting |
| NCT07605130 | Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced… | Intracranial Arteriosclerosis | Not Yet Recruiting |
| NCT07617155 | GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis | Hypertriglyceridemia Induced Acute Pancreatitis | Not Yet Recruiting |
| Phase 3 | |||
| NCT07376824 | Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint… | Diminished Ovarian Reserve (DOR) | Recruiting |
| NCT07347340 | Testing Herbal Pretreatment For IVF Success In Women With Low Ovarian Reserve | Diminished Ovarian Reserve (DOR) | Not Yet Recruiting |
| NCT07548671 | Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA | Transfusion-dependent Non-severe Aplastic Anemia | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT07068165 | A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment… | IgG4 Related Disease | Recruiting |
| Phase 2 | |||
| NCT07317414 | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | Recruiting |
| NCT06562166 | Online Adaptive Radiotherapy for Cervical Cancer | Cervical Cancer | Recruiting |
| NCT05139095 | Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Neoplasia | Recruiting |
| NCT06568705 | Hypofractionated Online Adaptive Radiotherapy of Breast Cancer | Breast Cancer | Recruiting |
| NCT07014150 | Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for… | Hepatocellular Carcinoma Resectable | Recruiting |
| NCT07540286 | A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism | Hypoparathyroidism | Recruiting |
| NCT06949215 | 68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex… | ccRCC | Recruiting |
| NCT07355764 | MA-CRC-II-016 SHR-1811 | mCRC | Not Yet Recruiting |
| NCT07400250 | Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With… | Primary Immune Thrombocytopenia (ITP) | Not Yet Recruiting |
| NCT07453368 | Orelabrutinib in the Treatment of Relapsed/Refractory AIHA | Autoimmune Hemolytic Anemia (AIHA) | Not Yet Recruiting |
| NCT06241547 | PONV Prevention Via Percutaneous Nerve Electrical Stimulation on PC6 | Postoperative Nausea and Vomiting | Active, Not Recruiting |
| NCT07558434 | CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA | Severe Aplastic Anemia (SAA) | Not Yet Recruiting |
| NCT07572084 | Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia | Aplastic Anemia | Not Yet Recruiting |